Canaccord Genuity Group Has Lowered Expectations for Repligen (NASDAQ:RGEN) Stock Price

Repligen (NASDAQ:RGEN - Get Free Report) had its target price lowered by Canaccord Genuity Group from $170.00 to $150.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage presently has a "hold" rating on the biotechnology company's stock. Canaccord Genuity Group's price objective indicates a potential upside of 15.38% from the stock's current price.

Several other equities research analysts also recently weighed in on the stock. Royal Bank of Canada upped their target price on shares of Repligen from $203.00 to $205.00 and gave the company an "outperform" rating in a research note on Friday, February 21st. TD Cowen initiated coverage on Repligen in a research note on Monday, February 10th. They set a "buy" rating and a $200.00 price objective on the stock. JPMorgan Chase & Co. lifted their target price on Repligen from $190.00 to $200.00 and gave the stock an "overweight" rating in a research report on Friday, February 21st. StockNews.com raised Repligen from a "sell" rating to a "hold" rating in a research report on Friday, April 4th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $180.00 price objective on shares of Repligen in a report on Friday, February 21st. One analyst has rated the stock with a sell rating, six have issued a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $176.82.

Repligen Stock Down 1.6 %

Shares of NASDAQ:RGEN traded down $2.10 during trading on Wednesday, hitting $130.00. The company's stock had a trading volume of 753,355 shares, compared to its average volume of 708,300. The company has a market capitalization of $7.30 billion, a PE ratio of -254.90, a PEG ratio of 4.54 and a beta of 1.27. Repligen has a fifty-two week low of $102.97 and a fifty-two week high of $182.52. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. The stock's 50-day moving average price is $140.37 and its two-hundred day moving average price is $145.73.

Repligen (NASDAQ:RGEN - Get Free Report) last released its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, beating the consensus estimate of $0.41 by $0.03. The company had revenue of $167.55 million during the quarter, compared to analysts' expectations of $167.58 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. As a group, sell-side analysts expect that Repligen will post 1.72 EPS for the current year.

Insiders Place Their Bets

In other Repligen news, Director Margaret Pax purchased 250 shares of the stock in a transaction dated Monday, March 17th. The shares were bought at an average cost of $150.69 per share, with a total value of $37,672.50. Following the completion of the acquisition, the director now owns 1,043 shares of the company's stock, valued at approximately $157,169.67. This trade represents a 31.53 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 1.20% of the stock is owned by insiders.

Hedge Funds Weigh In On Repligen

Several large investors have recently bought and sold shares of RGEN. Ballentine Partners LLC boosted its stake in Repligen by 4.0% in the 4th quarter. Ballentine Partners LLC now owns 1,879 shares of the biotechnology company's stock worth $270,000 after purchasing an additional 72 shares during the period. CIBC Asset Management Inc boosted its position in shares of Repligen by 5.0% during the fourth quarter. CIBC Asset Management Inc now owns 1,706 shares of the biotechnology company's stock worth $246,000 after buying an additional 81 shares during the period. MML Investors Services LLC grew its holdings in shares of Repligen by 2.7% during the third quarter. MML Investors Services LLC now owns 3,383 shares of the biotechnology company's stock worth $503,000 after buying an additional 89 shares in the last quarter. GAMMA Investing LLC raised its position in Repligen by 15.2% in the 4th quarter. GAMMA Investing LLC now owns 684 shares of the biotechnology company's stock valued at $98,000 after buying an additional 90 shares during the last quarter. Finally, Louisiana State Employees Retirement System lifted its stake in Repligen by 0.7% in the 4th quarter. Louisiana State Employees Retirement System now owns 14,500 shares of the biotechnology company's stock valued at $2,087,000 after acquiring an additional 100 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.